We’re excited to announce that 𝗙𝗿𝗼𝗻𝘁𝗶𝗲𝗻𝘁 𝟰𝟬𝟬𝗺𝗴 (𝗜𝗡𝗡: 𝗣𝗮𝘇𝗼𝗽𝗮𝗻𝗶𝗯) is now available in Bosnia and Herzegovina, following its launch at the end of March. This marks one of the first generic launches of Pazopanib in the Western Balkans – a step forward in expanding access to oncology treatments in the region. Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma and soft tissue sarcoma.

At Zdravlje, we are committed to making high-quality, affordable therapies available to patients and healthcare systems across Central and Eastern Europe. Cancer presents an enormous healthcare and socio-economic burden to our region and this launch is a step in reducing this impact.

A huge thank you to our Regulatory and Supply Chain teams, as well as our partners —your hard work and dedication made this happen!

Onward to better healthcare solutions!